WEBINAR

CV RISK IN PATIENTS WITH TYPE 2 DIABETES & CVD

Getting to the heart of diabetes

Thursday, 18 October 2018 7.00 – 8.00pm AEDT







GETTING TO THE HEART OF DIABETES

The interdisciplinary discussion will focus on:

- Evidence-based strategies to reduce CV risk for patients with diabetes and CVD
- Advice on how to individualise choice of blood glucose-lowering agents
- The latest Australian blood glucose treatment algorithm for type 2 diabetes
- An update on the latest CV outcome trial data and how this impacts your practice










DIABETES & CVD

Common clinical presentations:

- Diabetes diagnosed at the time of a CV event
- Patients with long-standing diabetes who develop CVD

PATIENTS WITH TYPE 2 DIABETES IN AUSTRALIAN PRIMARY CARE¹









MEET JUDY

VISIT 1

- ▶ 57-year-old receptionist
- Asking for repeat prescriptions for her diabetes medicines
- You take her history, conduct an examination and request pathology tests









JUDY'S HISTORY

MEDICAL HISTORY

Type 2 diabetes – 5 years ago

NSTEMI & right coronary artery stent – 3 years ago

Elevated blood pressure – diagnosed at the time of NSTEMI

SOCIAL HISTORY

Divorced & lives alone, 2 adult married sons

Social drinker (2-3 glasses when out)

Walks 2-3 times a week and tries to be careful with her diet, has found it hard to lose weight

Current medicines list

MEDICINE	DOSE	INDICATION
Metformin immediate-release	1 g twice daily	Type 2 diabetes, for 5 years
Gliclazide MR	120 mg once daily	Type 2 diabetes, for 3 years
Telmisartan	40 mg once daily	Hypertension, secondary prevention of CVD
Aspirin	100 mg once daily	Secondary prevention of CVD







JUDY'S RESULTS

Examination

BP: 136/84 mmHg

Pulse rate: 70 bpm, regular

BMI: 28.1 kg/m²

No peripheral neuropathy

No retinopathy

Pathology results

 $eGFR > 90 \text{ mL/min/1.73m}^2 \text{ (normal)}$

UACR < 3.5 mg/mmol (normal)

Pathology results continued

Lipid profile	Result	Target
Total cholesterol	4.3 mmol/L	< 4.0 mmol/L
LDL-C	2.4 mmol/L	< 1.8 mmol/Lª
HDL-C	0.8 mmol/L	> 1.0 mmol/L
Non-HDL-C	3.5 mmol/L	< 2.5 mmol/L
Triglycerides	2.4 mmol/L	< 2.0 mmol/L
HbA _{1c}	67 mmol/mol	\leq 53 mmol/mol
	(8.3%)	(≤ 7.0%) ^b







^a For secondary prevention ^b Targets should be individualised

AUDIENCE POLLING QUESTION

How would you manage Judy's glycaemic control?

- a) Increase the dose of her current diabetes medicines
- b) Add a third blood glucose lowering agent
- c) Replace one of her existing blood glucose lowering agents
- d) Don't change her medicines but counsel her on improving her diet and lifestyle







AUSTRALIAN BLOOD GLUCOSE TREATMENT ALGORITHM FOR TYPE 2 DIABETES



All patients should receive education regarding lifestyle measures: healthy diet, physical activity and weight control Determine the individual's HbA, target - this will commonly be ≤ 53 mmol/mol (7.0%). If not at target, or if an HbA, reduction of ≥ 0.5% is not achieved after 3 months, move down the algorithm.

First line: Metformin is the usual first-line therapy unless contraindicated or not tolerated

DPP-4 SGLT2 SU Insulin Metformin Acarbose inhibitor inhibitor

- If HbA, target not achieved in 3 months:
- . check and review current therapies, stop any that fail to improve glycaemic control
- check patient understanding and self-management

- · review use of therapies
- . exclude other comorbidities/therapies impacting on glycaemic control
- · reinforce lifestyle measures

Second line: If metformin was not used first line, add it now, if not contraindicated.

SU

Choice of second line agent to add to metformin should be guided by clinical factors/considerations, contraindications, side effect profile and cost.

SGLT2 DPP-4 inhibitor inhibitor GLP-1RA

Insulin*

Acarbose

TZD

TZD

If HbA, target not achieved in 3 months:

- . check and review current therapies, stop any that fail to improve glycaemic control
- . check patient understanding and self-management
- · review use of therapies
- · exclude other comorbidities/therapies impacting on glycaemic control
- * reinforce lifestyle measures

Third line: Consider triple oral therapy or addition of GLP-1RA or insulin

DPP-4 inhibitor

SGLT2 inhibitor SU

GLP-1RA

Insulin*

Acarbose

TZD

If HbA, target not achieved in 3 months:

- . check and review current therapies, stop any that fail to
- improve glycaemic control . check patient understanding and self-management

- exclude other comorbidities/therapies impacting on glycaemic control
- * reinforce lifestyle measures

THEN

If on triple oral therapy

Switch ≥ 1 oral agent basal or OR to GLP-1RA or insulin* premixed or another oral agent†

If on GLP-1RA Change to

Add basal or premixed

Add SGLT2 inhibitor or GLP-1RA or basal bolus or basal plus insulin or change to premixed insulin

If on basal insulin*

PBS = Pharmaceutical Benefits Scheme, SU-sulfonylurea, TZD- thiazolidinedione, DPP.4 = dipeptidyl peptidase-4, GLP-1RA- glucagon like peptide 1 receptor agonist, SGLT2 - sodium glucose transporter.

Dark blue boxes indicate usual therepeutic strategy (order is not meant to denote any specific preference); usual refers to commonly available, evidence based, cost effective ferapy.

White boxes indicate alternate approaches (order is not meant to denote any specific preference).

Red outlines indicate the classes of glucose lowering agent that include PBS subsidies of products.

Red outlines indicate the classes of glucose lowering agent that include PBS subsidies of products.

Unless metformin is contraindicated, or not tolerated, it is often therapeutically useful to continue it in combination with insulin.

† Switching an oral agent is likely to have the smallest impact on glycaemia.

t2d.diabetessociety.com.au







DECISIONAID

Lifestyle and metformin for type 2 diabetes

If you have type 2 diabetes, you may need to take medicines in addition to making lifestyle changes, to help keep your blood glucose levels under control. Follow these steps and talk with your health professional to make decisions about your treatment.

1 Informing your decision

Blood glucose levels that are consistently above the normal range can cause serious complications: vision loss, kidney disease, foot and leg problems, and an increased risk of stroke and heart disease. It's important to find the best treatment to keep your blood glucose levels within your target range.

For some people with type 2 diabetes, making sufficient lifestyle changes is enough to control blood glucose levels. For others, these changes will not be enough over time and a glucose lowering medicine may need to be considered.

Comparing your current options

Currently, you have two treatment options:

- making lifestyle changes, including healthy eating, achieving or maintaining a healthy weight, being physically active, stopping smoking and reducing alcohol use.
- taking a glucose-lowering medicine, called metformin, as well as making these lifestyle changes.

Use the table below to compare the benefits and risks of each treatment option.

LIFESTYLE CHANGES ALONE

What's involved?

- Follow the Australian Dietary Guidelines and eat a variety of nutritious foods.
- Be physically active for at least 30 minutes almost every day.
- Reach and maintain a healthy body weight.
- The extent of changes you need to make depends on your current lifestyle and blood glucose levels.

What are the benefits?

- Some people with diabetes are able to manage their blood glucose levels with lifestyle changes alone.
- Lifestyle changes are also good for your overall health and may benefit other health conditions.

What are the risks and common side effects?

Making lifestyle changes can be hard. Your blood glucose may stay too high and you might have to consider starting metformin in the future.

METFORMIN AND LIFESTYLE CHANGES

- Metformin is the first prescription medicine most people with type 2 diabetes start taking.
- Metformin is a tablet you take 1 to 3 times a day.
- Metformin is a medicine that you will need to take long-term.
- Continue to make and sustain lifestyle changes.

Metformin is effective in helping people with diabetes manage their blood glucose levels.

- Metformin has been used for many years so its effects on the body are well understood, it does not cause weight gain and may help weight loss.
- You may get diarrhoea, heartburn, nausea and stomach pain, especially when you first start taking the medicine. Side effects usually only last a few weeks and can be reduced by taking the medicine with food.

Deciding what matters most to you Respond to the statements below to work out what matters most to you about your current treatment options. These answers can help you prepare for discussions with your health professional Tick the box that best describes how you feel. I want to try controlling my blood glucose levels without medicines : I am worried about managing medicine side effects. I am concerned about taking medicines long term. I feel confident I can make sufficient lifestyle changes to lower blood glucose levels. What else matters to you? Do you know enough to make a decision? Think about the information you have read and talked about with your health professional while considering the questions below. Do you know enough about the Talk with your diabetes team or other health professionals. benefits and risks of each option? Join a support group (in person or online) and talk with others who are taking metformin. They can give you their view on the benefits and risks and tell you about their Are you clear about the benefits experience of the medicine. and risks that matter most to you? Discuss your options and what matters most to you with a trusted person (for example a family member or friend). Visit the NPS MedicineWise website www.nps.org.au/diabetes Do you have enough support and or call Medicines Line on 1300 MEDICINE. advice to make a decision? Visit the Diabetes Australia website Yes No www.diabetesaustralia.com.au or phone 1300 136 588. What is your decision? Lifestyle changes alone. Metformin as well as lifestyle changes. Now that you have followed these steps, speak with your health professional about your treatment decision.

nps.org.au/diabetes

0.206/nPS Medicine/Wise, Published July 20%, ASRI GI 062-034 361 Level (346A Strobeth St. Surry Hills NSW 200), Independent

Not-for-profit. Evidence-based Developed with funding from the Australian Government Department of Health. The information provided is

seeking it because of something herein. Medicines information changes, and may not be accusate when you access it. To the fullest extent

permitted by law NPS MedicheWise disclaims all liability (including without limitation for regispence) for any loss, damage, or injury resulting



NPS MEDICINEWISE





THANK YOU

Thank you for attending.

Please click on "feedback survey" below.





